V-Bio Ventures, a Ghent-based independent venture capital firm focusing on biotech, was closed.
Nearly all of the limited partners in their first fund are now participating in this second fund. Multiple new investors are also involved. V-Bio Fund 1 and V-Bio Ventures together will have more than EUR185m under management.
Led by Christina Takke and Willem Broekaert, Founding Managing Partners, V-Bio Ventures focuses specifically on the segment of young pioneering biotech companies and its strategy to invest in transformational companies in the medical and agricultural sectors. V-Bio Fund 2 will maintain its relationship with VIB, Europe’s leading life sciences institute, to access deals from the renowned research center that has spun out multiple successful biotech companies such as Ablynx.
The firm plans to increase their team from seven investment professionals to nine, with a scientific background and an abundance of experience from investment funds and biotech companies. Shelley Margetson, a senior executive from multiple European biotechnology companies including Merus (MRUS) on Nasdaq, joined the fund to become Managing Partner. Ward Capoen who has been with V-Bio Ventures from the beginning of the fund’s inception, will be promoted to Partner.
V-Bio Ventures, which was established in 2015, has invested in nineteen businesses, co-created seven, and helped bring eight therapies closer to patients. Syndesi Therapeutics was purchased by AbbVie earlier this year for as high as $1bn. Agomab, Precirix, and Agomab also raised EUR 63m & 80m from international investment syndicates.